Pharming Group N.V. (PHAR) Stock Forecast
PHAR analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 4 analysts
- Price target
- $34.35 average of analyst targets
- Upside to target
- +267.0% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $0.12
- 52-week range
- $9.36 – $21.18
PHAR analyst ratings
4 analystsNumber of analysts at each rating.
PHAR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PHAR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.30 | $0.30 | $0.30 | $0.01 | +2,900.0% | 1 |
| Current fiscal year (2026) | $0.61 | $0.61 | $0.61 | $0.04 | +1,425.0% | 1 |
| Next fiscal year (2027) | $0.07 | $0.05 | $0.08 | $0.61 | −89.3% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PHAR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $103.5M | $97.5M | $108.1M | +6.4% | 4 |
| Current fiscal year (2026) | $383.4M | $369.8M | $394.6M | +1.9% | 4 |
| Next fiscal year (2027) | $417.3M | $391.7M | $452.0M | +8.8% | 4 |
PHAR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PHAR revenue: reported and forecast
PHAR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.08 | $0.20 | $0.20 | $0.20 | $0.30 | +265.9% | 0 up · 0 down |
| Current fiscal year (2026) | $0.23 | $0.46 | $0.46 | $0.46 | $0.61 | +164.9% | 0 up · 0 down |
| Next fiscal year (2027) | $0.07 | $0.31 | $0.31 | $0.31 | $0.07 | 0.0% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PHAR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PHAR beat in 5 of 12.
What analysts expect from PHAR
4 analysts cover Pharming; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $34.35, 267.0% above the latest close of $9.36. Analysts expect earnings of $0.61 per share for 2026, +1,425.0% from a year earlier. For 2027 the average estimate is $0.07 per share on revenue of $417.3 million. Pharming beat the EPS estimate in 5 of the last 12 quarters.
Related: PHAR income statement, PHAR key metrics, PHAR chart. See the PHAR stock overview for the latest quote and news.
PHAR forecast FAQ
What is Pharming's price target?
The average analyst price target for Pharming is $34.35, 267.0% above the latest close of $9.36.
Is Pharming a buy, hold or sell?
Of 4 analysts covering Pharming, 4 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Pharming's EPS forecast?
Analysts forecast $0.61 per share for 2026 (range $0.61 to $0.61); for 2027 the estimate is $0.07.
What is Pharming's revenue forecast?
The average revenue estimate for 2026 is $383.4 million, growth of 1.9%; for 2027 it is $417.3 million.
When does Pharming report earnings?
Pharming is expected to report results for the quarter ending September 30, 2026 on November 5, 2026; the EPS estimate is $0.12.
Does Pharming usually beat earnings estimates?
Pharming reported EPS at or above the analyst estimate in 5 of the last 12 quarters.